Discovery of this novel negative feedback regulation could explain the limited success of targeting Akt by cancer therapeutics in some contexts [65], as inhibition of Akt is likely to lead to loss of the feedback signal and activation of Akt-independent pro-growth signalling downstream of PIP3. Here, AKT1 is linked to cancer.